Psychedelics Market for Depression to Reach $11 Billion by 2035, Wells Fargo Projects

The market for branded psychedelic treatments for depression is projected to reach $11 billion by 2035, according to a new research report from Wells Fargo. The bank's analysis suggests significant growth potential driven by increasing physician adoption and the development of new therapies with improved efficacy and dosing schedules.

Market Projections and Physician Outlook

Wells Fargo's forecast is underpinned by a survey of 20 physicians who collectively treat more than 7,500 patients with major depressive disorder and treatment-resistant depression (TRD). The survey revealed a willingness among these specialists to prescribe psychedelic treatments to approximately 23% of their TRD patients.

Based on these findings, the bank projects that branded psychedelics will eventually achieve a 14% market penetration in the U.S. TRD population. This would represent a substantial increase from the current market share of approximately 2%, held by the existing treatment Spravato.

The Current Landscape

The report notes that Spravato, the leading psychedelic-based therapy currently on the market, is generating sales that annualize at more than $2 billion. Its adoption initially faced headwinds from skepticism over clinical data and strict regulatory requirements mandating certified centers and two-hour patient monitoring periods.

Ad

Wells Fargo identified Spravato's moderate efficacy and the need for maintenance dosing every two weeks as key limitations. These factors create a significant opportunity for new entrants developing therapies that may offer more durable effects and less frequent administration.

What to Watch in the Pipeline

The development pipeline is a key factor in the growth forecast, as most new psychedelics are expected to require fewer annual doses than Spravato. In its report, Wells Fargo highlighted several companies in the sector, including CMPS, DFTX, GHRS, and HELP.

The bank expressed a positive view on DFTX and HELP ahead of upcoming Phase 3 data, signaling potential catalysts for investors monitoring the emerging therapeutic category.